TrialAutopsyBuilt by Jawad Momani (Pwnedl0l)

Autopsy report · NCT05450562

Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors

Cause of deathFunding or business, also safety Automatic label, confidence 0.5, unverified. How labels are made.
“Early discontinuation based on strategic sponsor decision not driven by any safety concerns”

The sponsor’s own words in the registry.

Life of this trial

20222023202420252026Registered2022-07-05Started2022-09-20Stopped2025-12-22

Vital statistics

Status
Terminated
Phase
Phase 1, Phase 2
Sponsor
Sanofi
Sponsor type
Industry
Conditions
Neoplasm
Interventions
SAR444200; Atezolizumab
Participants
33
Sites
13
Countries
Canada, China, Singapore, South Korea, United States

Trials that died the same way

Look deeper

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.